Table 1 Dosing of iExosomes across experiments and relationship to clinical dose levels
Murine (average BW = 25 g) | NHP (average BW = 6 kg) | Human (average BW = 70 kg) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
iExo (1:1 Exo:siRNA, exp. as Exo protein) | siRNA or Exo | iExo (1:1 Exo:siRNA, exp. as Exo protein) | siRNA or Exo | iExo (1:1 Exo:siRNA, exp. as Exo protein) | siRNA or Exo | ||||||
mg/kg | mg/kg | mg per 25 g BW | mg/kg | mg/kg | mg per 6 kg BW | mg/kg | mg/kg | mg per 70 kg BW | Clinical Trial Dose Levels | ||
Preclinical anti-tumor studies (i.p.) | 0.04 | 0.04 | 0.001 | 0.0100 | 0.0100 | 0.00324 | 0.00324 | L1-L2* | *Clinical Trial equivalent | ||
NHP Imaging study (i.v. & i.p.) | 0.0110 | 0.0110 | 0.070 | ||||||||
NHP tox study (i.v) | 0.0021 | 0.0021 | 0.150 | L1* | *Clinical Trial equivalent | ||||||
Murine tox study (i.v.) | 0.026 | 0.026 | 0.66 | 0.0021 | 0.0021 | 0.150 | L1 | Clinical Trial (i.v.) | |||
0.053 | 0.053 | 1.32 | 0.0043 | 0.0043 | 0.300 | L2 | |||||
0.106 | 0.106 | 2.65 | 0.0086 | 0.0086 | 0.600 | L3 | |||||
0.0172 | 0.0172 | 1.200 | L4 | ||||||||
0.0344 | 0.0344 | 2.400 | L5 | ||||||||
0.0688 | 0.0688 | 4.800 | L6 | ||||||||
